OMIC vs. HLTH, AXDX, CARA, RPID, TLIS, BNGO, TBIO, PRPO, DRRX, and ACHL
Should you be buying Singular Genomics Systems stock or one of its competitors? The main competitors of Singular Genomics Systems include Cue Health (HLTH), Accelerate Diagnostics (AXDX), Cara Therapeutics (CARA), Rapid Micro Biosystems (RPID), Talis Biomedical (TLIS), Bionano Genomics (BNGO), Telesis Bio (TBIO), Precipio (PRPO), DURECT (DRRX), and Achilles Therapeutics (ACHL). These companies are all part of the "medical" sector.
Singular Genomics Systems (NASDAQ:OMIC) and Cue Health (NASDAQ:HLTH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.
65.8% of Singular Genomics Systems shares are owned by institutional investors. Comparatively, 45.5% of Cue Health shares are owned by institutional investors. 22.2% of Singular Genomics Systems shares are owned by company insiders. Comparatively, 12.5% of Cue Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Singular Genomics Systems received 12 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 48.15% of users gave Singular Genomics Systems an outperform vote while only 7.14% of users gave Cue Health an outperform vote.
Singular Genomics Systems has higher earnings, but lower revenue than Cue Health. Singular Genomics Systems is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.
Singular Genomics Systems has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Cue Health has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Cue Health has a net margin of -526.48% compared to Singular Genomics Systems' net margin of -3,257.30%. Singular Genomics Systems' return on equity of -45.33% beat Cue Health's return on equity.
In the previous week, Singular Genomics Systems' average media sentiment score of 0.71 beat Cue Health's score of -0.09 indicating that Singular Genomics Systems is being referred to more favorably in the media.
Singular Genomics Systems presently has a consensus target price of $0.68, suggesting a potential upside of 54.11%. Cue Health has a consensus target price of $3.00, suggesting a potential upside of 2,190.08%. Given Cue Health's higher probable upside, analysts plainly believe Cue Health is more favorable than Singular Genomics Systems.
Summary
Singular Genomics Systems beats Cue Health on 11 of the 15 factors compared between the two stocks.
Get Singular Genomics Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Singular Genomics Systems Competitors List
Related Companies and Tools
